Obesity and liver disease

doi:10.1053/beem.2002.0225

Best Practice & Research Clinical Endocrinology & Metabolism

Volume 16, Issue 4, December 2002, Pages 703-716

https://doi.org/10.1053/beem.2002.0225 Get rights and content

Abstract

Non-alcoholic steatohepatitis (NASH) is a disease of emerging identity and importance. It is frequently associated with obesity, especially visceral fat, and is intimately related to fatty liver and markers of the insulin resistance syndrome. Both the prevalence and the severity of liver steatosis are related to body mass index, waist circumference, hyperinsulinaemia, hypertriglyceridaemia and impaired glucose tolerance or type 2 diabetes. The identification of obese patients who may progress from steatosis to NASH and from NASH to fibrosis/cirrhosis is an important clinical challenge. Substantial weight loss is accompanied by a marked attenuation of insulin resistance and related metabolic syndrome and, concomitantly, by a remarkable regression of liver steatosis in most patients, although increased inflammation may be detected in some subjects. Thus, NASH may be considered as another disease of affluence, as is the insulin resistance syndrome, and perhaps being part of it, especially in obese patients.

References (101)

O James et al.
Non-alcoholic steatohepatitis: another disease of affluence
Lancet
(1999)
V Ratziu et al.
Liver fibrosis in overweight patients
Gastroenterology
(2000)
C Garcia Monzon et al.
Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity
Journal of Hepatology
(2000)
JB Dixon et al.
Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese
Gastroenterology
(2001)
CP Day et al.
Steatohepatitis: a tale of two ‘hits’?
Gastroenterology
(1998)
LM Kaplan
Leptin, obesity, and liver disease
Gastroenterology
(1998)
K Tobe et al.
Relationship between serum leptin and fatty liver in Japanese male adolescent university students
American Journal of Gastroenterology
(1999)
A Uygun et al.
Serum leptin levels in patients with nonalcoholic steatohepatitis
American Journal of Gastroenterology
(2000)
Y Lee et al.
Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia
Journal of Biological Chemistry
(2001)
NK Saxena et al.
Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice
Hepatology
(2002)

L Valenti et al.

Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease

Gastroenterology

(2002)

S Nair et al.

Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis

American Journal of Gastroenterology

(2001)

AJ Sanyal et al.

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

Gastroenterology

(2001)

S Yang et al.

Mitochondrial adaptations to obesity-related oxidant stress

Archives of Biochemistry and Biophysics

(2000)

GA MacDonald et al.

More clues to the relationship between hepatic iron and steatosis. An association with insulin resistance? Editorial

Gastroenterology

(1999)

DK George et al.

Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis

Gastroenterology

(1998)

A Guillygomarc'h et al.

Venesection therapy of insulin-resistance-associated hepatic iron overload

Journal of Hepatology

(2001)

FS Facchini et al.

Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease

Gastroenterology

(2002)

D Clain et al.

Fatty liver disease in morbid obesity

Gastroenterology Clinics of North America

(1987)

JT Galambos et al.

Relationship between 505 paired liver tests and biopsies in 242 obese patients

Gastroenterology

(1978)

S Naveau et al.

Excess weight as a risk factor for alcoholic liver disease

Hepatology

(1997)

LE Adinolfi et al.

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

Hepatology

(2001)

ME Rinella et al.

Body mass index as a predictor of hepatic steatosis in living liver donors

Liver Transplantation

(2001)

J Kral et al.

Body fat topography as an independent predictor of fatty liver

Metabolism

(1993)

CA Matteoni et al.

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

Gastroenterology

(1999)

G Marchesini et al.

Association of non-alcoholic fatty liver disease with insulin resistance

American Journal of Medicine

(1999)

H Cortez-Pinto et al.

Non-alcoholic fatty liver: another feature of the metabolic syndrome?

Clinical Nutrition

(1999)

IR Willner et al.

Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease

American Journal of Gastroenterology

(2001)

MR Teli et al.

The natural history of non-alcoholic fatty liver: a follow-up study

Hepatology

(1995)

A Poonawala et al.

Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study

Hepatology

(2000)

V MD Struben et al.

Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds

American Journal of Medicine

(2000)

V Paradis et al.

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

Hepatology

(2001)

M Charlton et al.

Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease

Liver Transplantation

(2001)

T Ueno et al.

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver

Journal of Hepatology

(1997)

DG Fong et al.

Metabolic and nutritional considerations in nonalcoholic fatty liver

Hepatology

(2000)

G Marchesini et al.

Metformin in non-alcoholic steatohepatitis

Lancet

(2001)

SH Caldwell et al.

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

American Journal of Gastroenterology

(2001)

T Andersen et al.

Hepatic effects of dietary weight loss in morbidly obese subjects

Journal of Hepatology

(1991)

SG Sheth et al.

Nonalcoholic steatohepatitis

Annals of Internal Medicine

(1997)

CP Day

Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?

Gut

(2002)

EM Brunt

Nonalcoholic steatohepatitis: definition and pathology

Seminars in Liver Disease

(2001)

A Lonardo

Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?

Digestive Diseases

(1999)

Y Falck-Ytter et al.

Clinical features and natural history of nonalcoholic steatosis syndromes

Seminars in Liver Disease

(2001)

AJ McCullough

Update on nonalcoholic fatty liver disease

Journal of Clinical Gastroenterology

(2002)

J Ludwig et al.

Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease

Mayo Clinical Proceedings

(1980)

PG Kopelman

Obesity as a medical problem

Nature

(2000)

G Guzzaloni et al.

Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test

International Journal of Obesity

(2000)

M Rashid et al.

Nonalcoholic steatohepatitis in children

Journal of Pediatric Gastroenterology and Nutrition

(2000)

M Mukai et al.

Various S-GOT/S-GPT ratios in nonviral liver disorders and related physical conditions and life-style

Digestive Diseases and Sciences

(2002)

P Angulo et al.

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis

Hepatology

(1999)

Cited by (108)

The effects of L-carnitine supplementation on lipid profiles in adults: A systematic review and dose-response meta-analysis
2024, PharmaNutrition
We aimed to conduct this meta-analysis to systematically assess the effects of L-carnitine supplementation on levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), total cholesterol (TC), Apolipoprotein A (Apo A) and Apolipoprotein B (Apo B) in adults.
A systematic search was done in databases such as PubMed, ISI Web of Science, the Cochrane Library, and Scopus to find acceptable articles up to April 2023. Randomized controlled trials (RCTs) evaluating the effects of L-carnitine on lipid profiles in adults were included considering the specified inclusion and exclusion criteria.
We included the 60 RCTs (n = 3933) with 64 effect sizes in this study. L-carnitine supplementation had a significant effect on TG (WMD= −10.33 mg/dl, P < 0.001), TC (WMD= −6.91 mg/dl, P = 0.032), LDL-C (WMD= −7.51 mg/dl, P < 0.001), HDL-C (WMD= 1.80 mg/dl, P = 0.007) in intervention, compared to a placebo group, in the pooled analysis. Moreover, we conducted the subgroup analyses that have shown L-carnitine supplementation had a reduction effect on TG in baseline ≥ 150 mg/dl, and in any trial duration (<12 and ≥12 weeks), intervention dose ≥ 2 g/day, in overweight (25–29.9 kg/m²) and obese (>30 kg/m²), in type ² diabetes and other health status. Also, L-carnitine significantly impacted TC in baseline ≥ 200 mg/dl, trial duration ≥ 12 weeks, intervention dose ≥ 2 g/day, obese (>30 kg/m²), and other health statuses.
Our results indicate L-carnitine significantly reduces the serum levels of TC, LDL-C, and TG and increases HDL-C, but it had no significant effect on the levels of apolipoproteins.
Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis
2023, Clinics and Research in Hepatology and Gastroenterology
Obeticholic acid (OCA) is the second-line therapy for primary biliary cholangitis (PBC), as well as an attractive candidate as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). This meta-analysis aims to assess the impact of OCA on lipid profiles and clinical outcomes in patients with PBC and MASH. A comprehensive systematic review and meta-analysis of randomized controlled trials (RCTs) from five major databases were conducted. Changes in lipid profiles from baseline were compared between groups receiving placebo and OCA. Efficacy outcomes were evaluated separately for PBC and MASH trials, while safety outcomes included pruritus, gastrointestinal disturbances, and headache. OCA treatment exhibited a significant increase in low-density lipoprotein cholesterol (LDL-C) (standardized mean difference [SMD] = 0.39; 95 % confidence interval [CI] = 0.15 to 0.63) and a decrease in high-density lipoprotein cholesterol (HDL-C) (SMD = −0.80; 95 % CI = −1.13 to −0.47) in both PBC and MASH patients compared to placebo. OCA demonstrated superior efficacy to placebo in treating PBC and MASH, evident in both primary and secondary outcomes. The incidence of pruritus was significantly higher with OCA compared to placebo (risk ratio = 1.78, 95 % CI = 1.42 to 2.25). OCA is more efficacious than a placebo in the treatment of PBC and MASH. However, caution is needed given the association of OCA use with a significant increase in LDL-C levels and a decrease in HDL-C levels among patients with these conditions.
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group
2021, Cancer Treatment Reviews
Citation Excerpt :
For CAYA cancer survivors at risk for late liver injury, the adoption of preventive health behaviors can prevent further liver injury. There are several non-cancer treatment-related risk factors for elevated liver enzymes in survivors that are also associated with liver disease in the general population, such as obesity and increased alcohol intake [30,37,46–48]. The surveillance recommendations for late liver injury for CAYA cancer survivors are shown in Table 2.
Survivors of childhood, adolescent and young adult (CAYA) cancer may develop treatment-induced chronic liver disease. Surveillance guidelines can improve survivors’ health outcomes. However, current recommendations vary, leading to uncertainty about optimal screening. The International Late Effects of Childhood Cancer Guideline Harmonization Group has developed recommendations for the surveillance of late hepatotoxicity after CAYA cancer.
Evidence-based methods based on the GRADE framework were used in guideline development. A multidisciplinary guideline panel performed systematic literature reviews, developed evidence summaries, appraised the evidence, and formulated recommendations on the basis of evidence, clinical judgement, and consideration of benefits versus the harms of the surveillance while allowing for flexibility in implementation across different health care systems.
The guideline strongly recommends a physical examination and measurement of serum liver enzyme concentrations (ALT, AST, gGT, ALP) once at entry into long-term follow-up for survivors treated with radiotherapy potentially exposing the liver (moderate- to high-quality evidence). For survivors treated with busulfan, thioguanine, mercaptopurine, methotrexate, dactinomycin, hematopoietic stem cell transplantation (HSCT), or hepatic surgery, or with a history of chronic viral hepatitis or sinusoidal obstruction syndrome, similar surveillance for late hepatotoxicity once at entry into LTFU is reasonable (low-quality evidence/expert opinion, moderate recommendation). For survivors who have undergone HSCT and/or received multiple red blood cell transfusions, surveillance for iron overload with serum ferritin is strongly recommended once at long-term follow-up entry.
These evidence-based, internationally-harmonized recommendations for the surveillance of late hepatic toxicity in cancer survivors can inform clinical care and guide future research of health outcomes for CAYA cancer survivors.
Glucose toxicity and lipotoxicity in type 2 diabetes: How to protect β-cell?
2020, Medecine des Maladies Metaboliques
Un des objectifs majeurs, par ailleurs difficile à atteindre, dans la prise en charge du diabète de type 2 est de protéger la cellule β. Cette stratégie permettrait d’éviter ou retarder la perte structurelle et fonctionnelle progressive qui aboutit à un effondrement inéluctable de l’insulinosécrétion et, donc, à un échappement du contrôle glycémique. La glucotoxicité et la lipotoxicité jouent, de concert, un rôle dans ce processus, et les corriger devrait contribuer à se rapprocher de l’objectif, voire permettre de récupérer la partie réversible du déficit fonctionnel de la cellule β. Nous décrirons les approches non médicamenteuses et pharmacologiques susceptibles d’atténuer les phénomènes de glucotoxicité et de lipotoxicité chez les patients diabétiques de type 2. Récemment, certains espoirs ont été apportés par les agonistes des récepteurs du glucagon-like peptide-1 (GLP-1) et les inhibiteurs des cotransporteurs sodium-glucose de type 2 (SGLT2).
One of the major goals, yet hard to be reached, in the management of type 2 diabetes (T2D) is to protect β-cell. This would avoid or retard the structural and functional progressive loss that leads to an inevitable exhaustion of insulin secretion and thereby a loss of glucose control. Both glucose toxicity and lipotoxicity play a role in this process so that the correction of these metabolic features should contribute to approach the objective, and even possibly restore the reversible part of the β-cell functional defect. We will describe the non-pharmacological and pharmacological approaches that may alleviate glucolipotoxicity in patients with T2D. Recently, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors rose some new hopes in this matter.
Metabolomic-based assessment reveals dysregulation of lipid profiles in human liver cells exposed to environmental obesogens
2020, Toxicology and Applied Pharmacology
Significant attention has been given to the potential of environmental chemicals to disrupt lipid homeostasis at the cellular level. These chemicals, classified as obesogens, are abundantly used in a wide variety of consumer products. However, there is a significant lack of information regarding the mechanisms by which environmental exposure can contribute to the onset of obesity and non-alcoholic fatty liver disease (NAFLD). Several studies have described the interaction of potential obesogens with lipid-related peroxisome proliferator-activated receptors (PPAR). However, no studies have quantified the degree of modification to lipidomic profiles in relevant human models, making it difficult to directly link PPAR agonists to the onset of lipid-related diseases. A quantitative metabolomic approach was used to examine the dysregulation of lipid metabolism in human liver cells upon exposure to potential obesogenic compounds. The chemicals rosiglitazone, perfluorooctanoic acid, di-2-ethylexylphthalate, and tributyltin significantly increased total lipids in liver cells, being diglycerides, triglycerides and phosphatidylcholines the most prominent. Contrarily, perfluorooctane sulfonic acid and the pharmaceutical fenofibrate appeared to lower total lipid concentrations, especially those belonging to the acylcarnitine, ceramide, triglyceride, and phosphatidylcholine groups. Fluorescence microscopy analysis for cellular neutral lipids revealed significant lipid bioaccumulation upon exposure to obesogens at environmentally relevant concentrations. This integrated omics analysis provides unique mechanistic insight into the potential of these environmental pollutants to promote diseases like obesity and NAFLD. Furthermore, this study provides a significant contribution to advance the understanding of molecular signatures related to obesogenic chemicals and to the development of alternatives to in vivo experimentation.
Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
2019, Diabetes and Metabolism
Patients with type 2 diabetes mellitus (T2DM) are exposed to non-alcoholic fatty liver disease (NAFLD), a comorbidity associated with cardiovascular disease and chronic kidney disease, and which may progress to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Sodium–glucose cotransporter type-2 (SGLT2) inhibitors are glucose-lowering agents that improve glucose control while promoting weight loss and lowering serum uric acid levels. These agents may exert cardiovascular and renal protection in T2DM patients with established cardiovascular disease. Recent findings from both randomized controlled trials and open-label studies have also shown that SGLT2 inhibitors are able to reduce fatty liver content, as assessed by different imaging techniques, and improve biological markers of NAFLD, especially serum liver enzymes, in patients with T2DM. In addition, there are emerging data to suggest a mechanism beyond the reduction of hyperglycaemia and body weight, and a potential role for the decrease in low-grade inflammation and oxidative stress associated with SGLT2 inhibitor therapy. This positive effect of SGLT2 inhibitors on NAFLD complements their already well-known effects on cardiovascular and chronic kidney diseases.

View all citing articles on Scopus

^*: Address for correspondence: Division of Diabetes, Nutrition & Metabolic Disorders, Department of Medicine, CHU Sart Tilman, B-4000 Liège, Belgium.

View full text

Regular ArticleObesity and liver disease

Abstract

Lancet

Gastroenterology

Journal of Hepatology

Gastroenterology

Gastroenterology

Gastroenterology

American Journal of Gastroenterology

American Journal of Gastroenterology

Journal of Biological Chemistry

Hepatology

Gastroenterology

American Journal of Gastroenterology

Gastroenterology

Archives of Biochemistry and Biophysics

Gastroenterology

Gastroenterology

Journal of Hepatology

Gastroenterology

Gastroenterology Clinics of North America

Gastroenterology

Hepatology

Hepatology

Liver Transplantation

Metabolism

Gastroenterology

American Journal of Medicine

Clinical Nutrition

American Journal of Gastroenterology

Hepatology

Hepatology

American Journal of Medicine

Hepatology

Liver Transplantation

Journal of Hepatology

Hepatology

Lancet

American Journal of Gastroenterology

Journal of Hepatology

Nonalcoholic steatohepatitis

Annals of Internal Medicine

Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?

Gut

Nonalcoholic steatohepatitis: definition and pathology

Seminars in Liver Disease

Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?

Digestive Diseases

Clinical features and natural history of nonalcoholic steatosis syndromes

Seminars in Liver Disease

Update on nonalcoholic fatty liver disease

Journal of Clinical Gastroenterology

Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease

Mayo Clinical Proceedings

Obesity as a medical problem

Nature

Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test

International Journal of Obesity

Nonalcoholic steatohepatitis in children

Journal of Pediatric Gastroenterology and Nutrition

Various S-GOT/S-GPT ratios in nonviral liver disorders and related physical conditions and life-style

Digestive Diseases and Sciences

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis

Hepatology

Regular Article
Obesity and liver disease